NOVABRIDGE BIOSCIENCES reports a Return on Equity (ROE) of -143.93%.

What is NBP's dividend yield?

NOVABRIDGE BIOSCIENCES offers a dividend yield of 0.00%.

What is NBP's Deepscope Quality Score?

Deepscope rates NBP's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy NBP?

Deepscope's AI Timing Score for NBP is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does NBP belong to?

NOVABRIDGE BIOSCIENCES is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

NBP (NASDAQ) Stock Analysis | NOVABRIDGE BIOSCIENCES

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-09 | FS: 2026-03-31)

NBP

NOVABRIDGE BIOSCIENCES

US:NASDAQ STOCK Healthcare >> Biotechnology News 93

USD 1.59

0.03 (1.92%) Day Change

Watchlist Portfolio Compare Chart

0.00

D/E

-143.9%

ROE

-127.6%

ROA

0.00%

Div Yield

NOVABRIDGE BIOSCIENCES
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 1.59 Price 0.03 (1.92%) Day Change	NEWS SCORE: 93

NBP, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...

Loading chart...

15 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	93
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.59
PBV / Sector	5.76 / 4.71
Earning Per Share	-0.40

PE / Sector	N/A / 17.58
PEG or PE/Growth / Sector	N/A / 0.53
Average 1M Daily Value	1.32 M GREAT
Average 1W Daily Value	0.76 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

43%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-4,184.42 / 468.85
NPM Average (%) / Sector	-4,473.18 / -1,531.69
NPM Change Average (%) / Sector	N/A / 5,028.65
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-127.59 / 31.69
ROA Average (%) / Sector	-122.93 / -353.18
ROA Change Average (%) / Sector	284.11 / 5,214.65 GREAT
ROE (%) / Sector	-143.93 / 10.58
ROE Average (%) / Sector	-172.51 / 27.64
ROE Change Average (%) / Sector	306.62 / 2,048.88 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 3.68

Registration Details

Analyze Date	2026-06-10 09:43:46
Symbol	NBP
Name	NOVABRIDGE BIOSCIENCES
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	115.65 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	190.24 / 8,889.42

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 2440 Research Boulevard, Rockville, MD, United States, 20850

Phone: 240 745 6330

Website: https://novabridge.com

Sector: Healthcare >> Biotechnology

Description: NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.